BSEMHealthcare · BiotechnologyThe 1 Wall Street analysts covering BioStem Technologies, Inc. hold a median 12-month price target of $7 — +97.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores BioStem Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BSEM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +97.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Nov 2022 | Zacks Investment Research | Initiates | Buy | $6.40 |
| 7 Nov 2022 | Zacks Investment Research | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BSEM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 56% of US stocks
Cheaper than 43% of US stocks
Cheaper than 73% of US stocks
Higher than 9% of US stocks
Higher than 90% of US stocks
Higher than 96% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 16% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioStem Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioStem Technologies outlined plans to expand into surgical applications, shift its revenue mix away from physician-office wound care, and move manufacturing of acquired products into its Florida facility following its BioTissue deal.
Why it matters — The strategy signals a potential repositioning of BioStem's business model and product mix that BSEM watchers would want to track.
BioStem Technologies announced that company management will present at the Sidoti MicroCap Virtual Conference. The announcement was made in a press release on August 14, 2026.
Why it matters — A BSEM watcher would care because the presentation offers management an opportunity to share the company's story with investors at a microcap-focused conference.
BioStem Technologies reported second-quarter revenue of $7.9 million, up from $6.1 million in the first quarter, as it continued transitioning to a hospital-focused commercial model. The growth was supported by higher hospital sales, expanded commercial coverage, and a full quarter of contribution from its acquired business.
Why it matters — A BSEM watcher would care because the higher revenue signals progress in the company's hospital-focused commercial strategy and the integration of its acquisition.
BioStem Technologies, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the transcript of that call.
Why it matters — The transcript provides BSEM watchers with direct access to management's discussion of the company's second-quarter financial results and operational highlights.
BioStem Technologies reported a Q2 loss of $0.52 per share, wider than the Zacks Consensus Estimate of a $0.50 loss and a decline from earnings of $0.11 per share a year ago. The quarter still beat revenue expectations, according to the report.
Why it matters — BSEM watchers would follow this release because it shows the company's quarterly loss widened year over year and came in slightly worse than analyst expectations despite a revenue beat.
The 1 Wall Street analysts covering BioStem Technologies, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering BioStem Technologies, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioStem Technologies, Inc. 42 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, BioStem Technologies, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +97.7% from the last close, and Ticker Nerd's factor model ranks BioStem Technologies, Inc. 42 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioStem Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
BioStem Technologies, Inc. returned -40.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
BioStem Technologies, Inc. is a regenerative biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts and tissue-based solutions for advanced wound care and regenerative therapies.
The most recent item we track (MarketBeat, 22 Aug 2026): "BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal". BioStem Technologies outlined plans to expand into surgical applications, shift its revenue mix away from physician-office wound care, and move manufacturing of acquired products into its Florida facility following its BioTissue deal.
BioStem Technologies, Inc. is a regenerative biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts and tissue-based solutions for advanced wound care and regenerative therapies. Its current product portfolio includes VENDAJE, VENDAJE AC, VENDAJE OPTIC, American Amnion, and related perinatal tissue products designed for use in wound covering, soft tissue protection, and ocular surface repair. The company uses its proprietary BioRetain processing method to preserve the natural properties of perinatal tissue while creating products for surgical and wound care settings. BioStem Technologies serves clinicians and healthcare providers across the United States, supporting applications in chronic wound management and tissue repair. Based in Pompano Beach, Florida, BioStem Technologies plays a specialized role in the life sciences market as a provider of biologic grafts and regenerative wound care products.
CEO Mr. Jason V. Matuszewski · 73 employees · United States · https://biostemtechnologies.com